xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05999747</url>
    </required_header>
    <id_info>
      <org_study_id>5354-CL-0303</org_study_id>
      <nct_id>NCT05999747</nct_id>
    </id_info>
    <brief_title>A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease</brief_title>
    <official_title>A Phase 3, Multicenter, Prospective, Randomized, Open-label Study for Intraoperative Ureter(s) Visualization When Using ASP5354 With Near-infrared Fluorescence (NIR-F) Imaging in Adult Participants Undergoing Minimally Invasive and Open Abdominopelvic Surgeries</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Astellas Pharma Global Development, Inc.</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Astellas Pharma Inc</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The ureter is the tube that carries urine from the kidneys to the bladder. It is difficult&#xD;
        for surgeons to see the ureter during abdominal surgery. This could lead to injuring the&#xD;
        ureter which, although rare, could be serious.&#xD;
  &#xD;
        This study is about a potential new medical dye, called ASP5354. This dye is injected into&#xD;
        the person at the start of surgery and is detected in the ureter. This is done by an imaging&#xD;
        machine which has an option called near infrared fluorescence, or NIR-F. Together they show&#xD;
        live images of specific parts of the body. In this study, ASP5354 is used with an imaging&#xD;
        machine with a NIR-F option to show live images of the ureter during surgery.&#xD;
  &#xD;
        People with kidneys that work properly and those with kidney problems can take part in this&#xD;
        study. The main goal of the study is to find out how clearly the ureter can be seen with&#xD;
        ASP5354 during surgery in people whose kidneys work properly or who have mild kidney&#xD;
        problems. To do this, the surgeons will inject ASP5354 into the person having surgery. Then,&#xD;
        the surgeons will compare images of the ureter with an imaging machine using normal white&#xD;
        light and with the NIR-F option. Imaging using normal white light is the standard way&#xD;
        surgeons see the ureter during surgery.&#xD;
  &#xD;
        People 18 years or older, with or without kidney disease, who were going to have certain&#xD;
        abdominal surgeries may be able to take part.&#xD;
  &#xD;
        Everyone taking part will receive ASP5354 during surgery, but how the imaging is done will&#xD;
        depend on which group they are in. Before surgery, the people whose kidneys work properly or&#xD;
        who have mild kidney problems will be assigned into 1 of 2 groups by chance alone. Images of&#xD;
        the ureter will be checked in 1 group using normal white light and the other group using&#xD;
        normal white light and NIR-F. People with more severe kidney problems will not be assigned to&#xD;
        1 of 2 groups: all images of the ureter will be checked using normal white light and NIR-F.&#xD;
  &#xD;
        At the start of surgery, the surgeon will inject ASP5354 into the person having surgery, then&#xD;
        will start recording a video of the surgery. Then, after 30 minutes, the surgeon will record&#xD;
        how well the ureter can be seen. This will be done by either using normal white light, or&#xD;
        normal white light and NIR-F, depending which group each person having surgery is assigned.&#xD;
        For the group to be checked with normal white light and NIR-F, the surgeon will do this check&#xD;
        every 30 minutes until the end of surgery. For the group to be checked with normal white&#xD;
        light only, the surgeon will only do this check after the first 30 minutes.&#xD;
  &#xD;
        During the study, people will visit the study hospital 3 times. The first visit is to check&#xD;
        if they can take part in the study. People will be asked about their medical history, have a&#xD;
        medical examination, and their vital signs checked (blood pressure and pulse rate). Also,&#xD;
        they will have some blood and urine tests. For women this may include a pregnancy test.&#xD;
        People will have their surgery at the second visit. This will be within 28 days of their&#xD;
        first visit. This includes having some blood and urine tests before, during, and after&#xD;
        surgery. Also, they will have a medical examination, an electrocardiogram (ECG) to check&#xD;
        their heart rhythm, and have their vital signs checked. After surgery, people will return to&#xD;
        the clinic 10 days later for a final check-up. They will be asked if they have had any&#xD;
        medical problems. Also, they will have a medical examination, have their vital signs checked,&#xD;
        and have blood and urine tests.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 30, 2023</start_date>
    <completion_date type="Anticipated">March 31, 2024</completion_date>
    <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
    <phase>Phase 3</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Intra-participant comparison in ureter conspicuity for white light (WL) versus near -infrared fluorescence (NIR F) for participants with normal renal function or mild renal impairment.</measure>
      <time_frame>Up to 45 minutes after ASP5354 administration (Day 1)</time_frame>
      <description>Conspicuity will be scored individually for each illumination mode using the 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Intra-participant comparison of ureter conspicuity scores for WL versus the average of all NIR-F time points for participants with normal renal function or mild renal impairment</measure>
      <time_frame>Up to end of surgery (Day1)</time_frame>
      <description>Conspicuity will be scored individually for each illumination mode using the 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intra-participant comparison of ureter conspicuity scores for WL timepoint versus the end of surgery score with NIR-F for participants with normal renal function or mild renal impairment</measure>
      <time_frame>Up to end of surgery (Day1)</time_frame>
      <description>Conspicuity will be scored individually for each illumination mode using the 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Quantification of ureter conspicuity for WL and NIR-F illumination modes for all participants</measure>
      <time_frame>Up to end of surgery (Day1)</time_frame>
      <description>Ureter conspicuity will be quantified by image analysis measuring the color contrast when ASP5354 is present in the ureter.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intra-participant difference in ureter conspicuity for WL versus NIR-F for participants with moderate or severe renal impairment</measure>
      <time_frame>Up to 45 minutes after ASP5354 administration (Day 1)</time_frame>
      <description>Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intra-participant comparison of ureter conspicuity scores for WL versus the average of all NIR-F scores for participants with moderate or severe renal impairment</measure>
      <time_frame>Up to end of surgery (Day1)</time_frame>
      <description>Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intra-participant comparison of ureter conspicuity scores for WL versus the end of surgery scores with NIR-F for participants with moderate or severe renal impairment</measure>
      <time_frame>Up to end of surgery (Day1)</time_frame>
      <description>Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intra-participant difference in ureter conspicuity for WL versus NIR-F for participants in all cohorts</measure>
      <time_frame>Up to 45 minutes after ASP5354 administration (Day 1)</time_frame>
      <description>Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intra-participant comparison of ureter conspicuity scores for WL versus the average of all NIR-F time points for participants in all cohorts</measure>
      <time_frame>Up to end of surgery (Day1)</time_frame>
      <description>Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intra-participant comparison of ureter conspicuity scores for WL versus the end of surgery score with NIR-F for participants in all cohorts</measure>
      <time_frame>Up to end of surgery (Day1)</time_frame>
      <description>Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with Treatment-emergent adverse events (TEAEs)</measure>
      <time_frame>Up to Day 15</time_frame>
      <description>Adverse events (AEs) will be coded using MedDRA. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A TEAE is defined as an AE observed after administration of the study intervention and up to the follow-up period.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with serious TEAEs</measure>
      <time_frame>Up to Day 15</time_frame>
      <description>A Serious Adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other medically important event. A serious TEAE is defined as an SAE observed after administration of the study intervention and up to the follow-up period.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with laboratory value abnormalities and/or AEs</measure>
      <time_frame>Up to Day 15</time_frame>
      <description>Number of participants with potentially clinically significant laboratory values</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with vital sign abnormalities and/or AEs</measure>
      <time_frame>Up to Day 15</time_frame>
      <description>Number of participants potentially clinically significant vital signs</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with electrocardiogram (ECG) /cardiac monitoring abnormalities and/or AEs</measure>
      <time_frame>Up to 2 hours post-surgery (Day 1)</time_frame>
      <description>Number of participants potentially clinically significant ECGs/cardiac monitoring</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetics (PK) of ASP5354 in plasma: concentration</measure>
      <time_frame>Up to 45 minutes after ASP5354 administration (Day 1)</time_frame>
      <description>Concentration will be recorded from the PK plasma samples collected</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>PK of ASP5354 in urine: concentration</measure>
      <time_frame>Up to end of surgery (Day 1)</time_frame>
      <description>Concentration will be recorded from the PK urine samples collected</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>PK of ASP5354 in urine: amount of ASP5354 excreted in urine (Ae)</measure>
      <time_frame>Up to end of surgery (Day1)</time_frame>
      <description>Ae will be recorded from the PK urine samples collected</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>PK of ASP5354 in urine: percentage of ASP5354 dose excreted into urine (Ae percentage)</measure>
      <time_frame>Up to end of surgery (Day 1)</time_frame>
      <description>Ae percentage will be recorded from the PK urine samples collected</description>
    </secondary_outcome>
    <number_of_arms>3</number_of_arms>
    <enrollment type="Anticipated">91</enrollment>
    <condition>Intraoperative Ureter Visualization</condition>
    <condition>Abdominolpelvic Surgery</condition>
    <arm_group>
      <arm_group_label>White Light/near-infrared fluorescence - Adults with normal renal function or mild renal impairment</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354</description>
    </arm_group>
    <arm_group>
      <arm_group_label>White Light - Adults with normal renal function or mild renal impairment</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354</description>
    </arm_group>
    <arm_group>
      <arm_group_label>White Light/near-infrared fluorescence - Adults with moderate or severe renal impairment</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Adult participants with moderate or severe renal impairment will receive a single dose of ASP5354</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>pudexacianinium chloride</intervention_name>
      <description>Intravenous</description>
      <arm_group_label>White Light - Adults with normal renal function or mild renal impairment</arm_group_label>
      <arm_group_label>White Light/near-infrared fluorescence - Adults with moderate or severe renal impairment</arm_group_label>
      <arm_group_label>White Light/near-infrared fluorescence - Adults with normal renal function or mild renal impairment</arm_group_label>
      <other_name>ASP5354</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Participant is scheduled to undergo minimally invasive or open abdominopelvic surgery&#xD;
               that may require ureter identification&#xD;
  &#xD;
            -  Participant has normal renal function or has varying degrees of chronic kidney disease&#xD;
               as defined by the National Kidney Foundation and calculated by individual estimated&#xD;
               glomerular filtration rate (eGFR) using the modification of diet in renal disease&#xD;
               formula&#xD;
  &#xD;
                 -  Adult normal/mild eGFR cohort: eGFR ≥ 60 mL/min&#xD;
  &#xD;
                 -  Adult moderate/severe eGFR cohort: eGFR ≥ 15 to &lt; 60 mL/min&#xD;
  &#xD;
            -  Female participant is not pregnant and at least 1 of the following conditions apply:&#xD;
  &#xD;
                 -  Not a woman of childbearing potential&#xD;
  &#xD;
                 -  Woman of childbearing potential who agrees to follow the contraceptive guidance&#xD;
                    from the time of informed consent through at least 30 days after study&#xD;
                    intervention administration.&#xD;
  &#xD;
            -  Female participant must agree not to breastfeed starting at the administration of&#xD;
               ASP5354 through 30 days after ASP5354 administration.&#xD;
  &#xD;
            -  Female participant must not donate ova starting at the administration of ASP5354&#xD;
               through 30 days after ASP5354 administration.&#xD;
  &#xD;
            -  Male participant with female partner(s) of childbearing potential (including&#xD;
               breastfeeding partner) must agree to use contraception through at least 30 days after&#xD;
               ASP5354 administration.&#xD;
  &#xD;
            -  Male participant must not donate sperm starting at the administration of ASP5354&#xD;
               through 30 days after ASP5354 administration.&#xD;
  &#xD;
            -  Male participant with pregnant partner(s) must agree to remain abstinent or use a&#xD;
               condom for the duration of the pregnancy from the start of ASP5354 administration&#xD;
               through 30 days after ASP5354 administration.&#xD;
  &#xD;
            -  Participant agrees not to participate in another interventional study while&#xD;
               participating in the present study.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Participant has any physical or psychiatric condition, which makes the participant&#xD;
               unsuitable for study participation.&#xD;
  &#xD;
            -  Participant is anticipated to require ureteral stenting during surgery.&#xD;
  &#xD;
            -  Participant has an active urinary tract infection requiring antibiotic therapy.&#xD;
  &#xD;
            -  Participant has moderate to severe cardiac disease that limits daily functioning (New&#xD;
               York Heart Association Class III to IV) or other medical conditions would impact&#xD;
               safety or study compliance.&#xD;
  &#xD;
            -  Participant has any clinically relevant laboratory abnormality that could&#xD;
               contraindicate surgery.&#xD;
  &#xD;
            -  Participant has a known or suspected hypersensitivity to ASP5354, indocyanine green&#xD;
               (ICG) or any components of the formulation used.&#xD;
  &#xD;
            -  Participant has had previous exposure to ASP5354.&#xD;
  &#xD;
            -  Participant has been administered ICG or other NIR-F imaging agents within 48 hours&#xD;
               prior to ASP5354 administration, with the exception of participants who receive ICG&#xD;
               for lymphatic mapping before the surgery.&#xD;
  &#xD;
            -  Participant has received any investigational therapy within 28 days or 5 half-lives,&#xD;
               whichever is longer, prior to screening.&#xD;
  &#xD;
            -  Participant is on hemodialysis, hemodiafiltration or peritoneal dialysis.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Medical Monitor</last_name>
      <role>Study Director</role>
      <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Astellas Pharma Global Development, Inc.</last_name>
      <phone>800-888-7704</phone>
      <email>astellas.registration@astellas.com</email>
    </overall_contact>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>August 14, 2023</study_first_submitted>
    <study_first_submitted_qc>August 14, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 21, 2023</study_first_posted>
    <last_update_submitted>August 14, 2023</last_update_submitted>
    <last_update_submitted_qc>August 14, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 21, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>ASP5354</keyword>
    <keyword>Pudexacianinium chloride</keyword>
    <keyword>Latrogenic ureteral injury</keyword>
    <keyword>Abdominopelvic surgery</keyword>
    <keyword>Near-infrared Fluorescence</keyword>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
      <ipd_info_type>Study Protocol</ipd_info_type>
      <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
      <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
      <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
      <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
      <ipd_url>https://www.clinicalstudydatarequest.com</ipd_url>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05999747
  org study id: 5354-CL-0303
  nct id: NCT05999747
  lead sponsor: 
  has dmc: No
  is fda regulated drug: Yes
  is fda regulated device: No
  The ureter is the tube that carries urine from the kidneys to the bladder. It is difficult
        for surgeons to see the ureter during abdominal surgery. This could lead to injuring the
        ureter which, although rare, could be serious.
  
        This study is about a potential new medical dye, called ASP5354. This dye is injected into
        the person at the start of surgery and is detected in the ureter. This is done by an imaging
        machine which has an option called near infrared fluorescence, or NIR-F. Together they show
        live images of specific parts of the body. In this study, ASP5354 is used with an imaging
        machine with a NIR-F option to show live images of the ureter during surgery.
  
        People with kidneys that work properly and those with kidney problems can take part in this
        study. The main goal of the study is to find out how clearly the ureter can be seen with
        ASP5354 during surgery in people whose kidneys work properly or who have mild kidney
        problems. To do this, the surgeons will inject ASP5354 into the person having surgery. Then,
        the surgeons will compare images of the ureter with an imaging machine using normal white
        light and with the NIR-F option. Imaging using normal white light is the standard way
        surgeons see the ureter during surgery.
  
        People 18 years or older, with or without kidney disease, who were going to have certain
        abdominal surgeries may be able to take part.
  
        Everyone taking part will receive ASP5354 during surgery, but how the imaging is done will
        depend on which group they are in. Before surgery, the people whose kidneys work properly or
        who have mild kidney problems will be assigned into 1 of 2 groups by chance alone. Images of
        the ureter will be checked in 1 group using normal white light and the other group using
        normal white light and NIR-F. People with more severe kidney problems will not be assigned to
        1 of 2 groups: all images of the ureter will be checked using normal white light and NIR-F.
  
        At the start of surgery, the surgeon will inject ASP5354 into the person having surgery, then
        will start recording a video of the surgery. Then, after 30 minutes, the surgeon will record
        how well the ureter can be seen. This will be done by either using normal white light, or
        normal white light and NIR-F, depending which group each person having surgery is assigned.
        For the group to be checked with normal white light and NIR-F, the surgeon will do this check
        every 30 minutes until the end of surgery. For the group to be checked with normal white
        light only, the surgeon will only do this check after the first 30 minutes.
  
        During the study, people will visit the study hospital 3 times. The first visit is to check
        if they can take part in the study. People will be asked about their medical history, have a
        medical examination, and their vital signs checked (blood pressure and pulse rate). Also,
        they will have some blood and urine tests. For women this may include a pregnancy test.
        People will have their surgery at the second visit. This will be within 28 days of their
        first visit. This includes having some blood and urine tests before, during, and after
        surgery. Also, they will have a medical examination, an electrocardiogram (ECG) to check
        their heart rhythm, and have their vital signs checked. After surgery, people will return to
        the clinic 10 days later for a final check-up. They will be asked if they have had any
        medical problems. Also, they will have a medical examination, have their vital signs checked,
        and have blood and urine tests.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Intra-participant comparison in ureter conspicuity for white light (WL) versus near -infrared fluorescence (NIR F) for participants with normal renal function or mild renal impairment.
  time frame: Up to 45 minutes after ASP5354 administration (Day 1)
  description: Conspicuity will be scored individually for each illumination mode using the 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)
  measure: Intra-participant comparison of ureter conspicuity scores for WL versus the average of all NIR-F time points for participants with normal renal function or mild renal impairment
  time frame: Up to end of surgery (Day1)
  description: Conspicuity will be scored individually for each illumination mode using the 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)
  measure: Intra-participant comparison of ureter conspicuity scores for WL timepoint versus the end of surgery score with NIR-F for participants with normal renal function or mild renal impairment
  time frame: Up to end of surgery (Day1)
  description: Conspicuity will be scored individually for each illumination mode using the 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)
  measure: Quantification of ureter conspicuity for WL and NIR-F illumination modes for all participants
  time frame: Up to end of surgery (Day1)
  description: Ureter conspicuity will be quantified by image analysis measuring the color contrast when ASP5354 is present in the ureter.
  measure: Intra-participant difference in ureter conspicuity for WL versus NIR-F for participants with moderate or severe renal impairment
  time frame: Up to 45 minutes after ASP5354 administration (Day 1)
  description: Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)
  measure: Intra-participant comparison of ureter conspicuity scores for WL versus the average of all NIR-F scores for participants with moderate or severe renal impairment
  time frame: Up to end of surgery (Day1)
  description: Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)
  measure: Intra-participant comparison of ureter conspicuity scores for WL versus the end of surgery scores with NIR-F for participants with moderate or severe renal impairment
  time frame: Up to end of surgery (Day1)
  description: Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)
  measure: Intra-participant difference in ureter conspicuity for WL versus NIR-F for participants in all cohorts
  time frame: Up to 45 minutes after ASP5354 administration (Day 1)
  description: Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)
  measure: Intra-participant comparison of ureter conspicuity scores for WL versus the average of all NIR-F time points for participants in all cohorts
  time frame: Up to end of surgery (Day1)
  description: Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)
  measure: Intra-participant comparison of ureter conspicuity scores for WL versus the end of surgery score with NIR-F for participants in all cohorts
  time frame: Up to end of surgery (Day1)
  description: Conspicuity will be scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 (least conspicuous) to 5 (most conspicuous)
  measure: Number of participants with Treatment-emergent adverse events (TEAEs)
  time frame: Up to Day 15
  description: Adverse events (AEs) will be coded using MedDRA. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A TEAE is defined as an AE observed after administration of the study intervention and up to the follow-up period.
  measure: Number of participants with serious TEAEs
  time frame: Up to Day 15
  description: A Serious Adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other medically important event. A serious TEAE is defined as an SAE observed after administration of the study intervention and up to the follow-up period.
  measure: Number of participants with laboratory value abnormalities and/or AEs
  time frame: Up to Day 15
  description: Number of participants with potentially clinically significant laboratory values
  measure: Number of participants with vital sign abnormalities and/or AEs
  time frame: Up to Day 15
  description: Number of participants potentially clinically significant vital signs
  measure: Number of participants with electrocardiogram (ECG) /cardiac monitoring abnormalities and/or AEs
  time frame: Up to 2 hours post-surgery (Day 1)
  description: Number of participants potentially clinically significant ECGs/cardiac monitoring
  measure: Pharmacokinetics (PK) of ASP5354 in plasma: concentration
  time frame: Up to 45 minutes after ASP5354 administration (Day 1)
  description: Concentration will be recorded from the PK plasma samples collected
  measure: PK of ASP5354 in urine: concentration
  time frame: Up to end of surgery (Day 1)
  description: Concentration will be recorded from the PK urine samples collected
  measure: PK of ASP5354 in urine: amount of ASP5354 excreted in urine (Ae)
  time frame: Up to end of surgery (Day1)
  description: Ae will be recorded from the PK urine samples collected
  measure: PK of ASP5354 in urine: percentage of ASP5354 dose excreted into urine (Ae percentage)
  time frame: Up to end of surgery (Day 1)
  description: Ae percentage will be recorded from the PK urine samples collected
  arm group label: White Light/near-infrared fluorescence - Adults with normal renal function or mild renal impairment
  arm group type: Experimental
  description: Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354
  arm group label: White Light - Adults with normal renal function or mild renal impairment
  arm group type: Experimental
  description: Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354
  arm group label: White Light/near-infrared fluorescence - Adults with moderate or severe renal impairment
  arm group type: Experimental
  description: Adult participants with moderate or severe renal impairment will receive a single dose of ASP5354
  intervention type: Drug
  intervention name: pudexacianinium chloride
  description: Intravenous
  arm group label: White Light - Adults with normal renal function or mild renal impairment
  arm group label: White Light/near-infrared fluorescence - Adults with moderate or severe renal impairment
  arm group label: White Light/near-infrared fluorescence - Adults with normal renal function or mild renal impairment
  other name: ASP5354
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Medical Monitor
  role: Study Director
  affiliation: Astellas Pharma Global Development, Inc.
  last name: Astellas Pharma Global Development, Inc.
  phone: 800-888-7704
  email: astellas.registration@astellas.com
  responsible party type: Sponsor
  sharing ipd: Yes
  ipd description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
  ipd info type: Study Protocol
  ipd info type: Statistical Analysis Plan (SAP)
  ipd info type: Clinical Study Report (CSR)
  ipd time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
  ipd access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
  ipd url: https://www.clinicalstudydatarequest.com